Methods, devices, and medicaments that include oxaliplatin are provided for use in the treatment of bladder cancer by locally administering oxaliplatin into the bladder of a patient to achieve a sustained concentration of oxaliplatin in urine in the bladder sufficient to produce a therapeutic concentration of oxaliplatin in bladder tissue. The oxaliplatin may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously release...

The present invention provides a method for treatment of cancer comprising administration of an arginine reducing compound and a chemotherapeutic/target therapeutic drug to a subject in need thereof. In one embodiment the cancer is liver cancer or prostate cancer. In another embodiment the arginine reducing compound is pegylated recombinant human arginase and the chemotherapeutic/target therapeutic drug is oxaliplatin everolimus paclitaxel or sorafenib.

The present invention solves the problem of providing an oxaliplatin-encapsulating liposome aqueous dispersion of high long-term preservation stability. The present invention provides an aqueous dispersion of liposomes encapsulating oxaliplatin, wherein the oxaliplatin-encapsulating liposome aqueous dispersion is characterized by containing 2-morpholinoethanesulfonic acid in an external aqueous phase.

Disclosed is an oxaliplatin-containing parenterally-administered pharmaceutical composition of improved stability. The parenterally-administered pharmaceutical composition is obtained by dissolving oxaliplatin and at least one species of C3 polyol in water. Additionally disclosed are a method for producing said composition and a method for inhibiting the generation of related substances in the aqueous solution of oxaliplatin.

An object of the present invention is to further enhance the antitumor effect when oxaliplatin is administered in combination with a combination drug containing tegafur gimeracil and oteracil potassium. According to the present invention by using oxaliplatin encapsulated in a liposome preparation combination therapy of oxaliplatin plus a combination drug containing tegafur gimeracil and oteracil potassium is revealed to show remarkably enhanced antitumor effect without increasing side effects.

This invention provides a method for increasing apoptosis in a cancer cell comprising contacting the cancer cell with (a) oxaliplatin and (b) C6-ceramide sequentially or concomitantly wherein the oxaliplatin and C6-ceramide are in amounts such that the apoptosis induced by the combination of oxaliplatin and C6-ceramide is greater than the apoptosis induced by contacting the cancer cell with either oxaliplatin alone or C6-ceramide alone. This invention also provides a method of decreasing the siz...

This invention provides a method for increasing apoptosis in a cancer cell comprising contacting the cancer cell with (a) oxaliplatin and (b) C6-ceramide, sequentially or concomitantly, wherein the oxaliplatin and C6-ceramide are in amounts such that the apoptosis induced by the combination of oxaliplatin and C6-ceramide is greater than the apoptosis induced by contacting the cancer cell with either oxaliplatin alone or C6-ceramide alone. This invention also provides a method of decreasing the s...